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Abstract
Background: In osteonecrosis the vascular supply of the bone is interrupted and the living cells die. The
inorganic mineral network remains intact until ingrowing blood vessels invade the graft. Accompanying osteoclasts
start to resorb the bone trabeculae and gradually replace the bone. If the osteonecrosis occurs in mechanically
loaded parts, like in the subchondral bone of a loaded joint, the remodelling might lead to a weakening of the bone
and, in consequence to a joint collapse. Systemic bisphosphonate treatment can reduce the resorption of necrotic
bone. In the present study we investigate if zoledronate, the most potent of the commercially available
bisphosphonates, can be used to reduce the amount or speed of bone graft remodeling.
Methods: Bone grafts were harvested and placed in a bone chamber inserted into the tibia of a rat. Host tissue
could grow into the graft through openings in the chamber. Weekly injections with 1.05 μg zoledronate or saline
were given subcutaneously until the rats were harvested after 6 weeks. The specimens were fixed, cut and stained
with haematoxylin/eosin and used for histologic and histomorphometric analyses.
Results: By histology, the control specimens were almost totally resorbed in the remodeled area and the graft
replaced by bone marrow. In the zoledronate treated specimens, both the old graft and new-formed bone
remained and the graft trabeculas were lined with new bone. By histomorphometry, the total amount of bone
(graft+ new bone) within the remodelled area was 35 % (SD 13) in the zoledronate treated grafts and 19 % (SD
12) in the controls (p = 0.001). Also the amount of new bone was increased in the treated specimens (22 %, SD
7) compared to the controls (14 %, SD 9, p = 0.032).
Conclusion: We show that zoledronate can be used to decrease the resorption of both old graft and new-
formed bone during bone graft remodelling. This might be useful in bone grafting procedure but also in other
orthopedic conditions, both where necrotic bone has to be remodelled i.e. after osteonecrosis of the knee and
hip and in Perthes disease, or in high load, high turnover conditions like delayed union, periprosthetic osteolysis
or bone lengthening operations. In our model an increased net formation of new bone was found which probably
reflects that new bone formed was retained by the action of the bisphosphonates rather than a true anabolic
effect.
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Osteonecrosis is hypothesised to be caused by insufficient
circulation [1]. It can occur after trauma or be the result of
other events or conditions that compromise the circula-
tion, such as corticosteroid treatment, scuba diving, sickle
cell anemia, alcoholism and pregnancy [2]. Necrotic bone
retains its load bearing capacity [3], but as revasculariza-
tion and remodelling starts, resorption and bone forming
will occur simultaneously. In mechanically loaded parts,
like in the subchondral bone of a loaded joint, the remod-
elling might lead to a weakening of the bone and, in con-
sequence, to a joint collapse [14,5,6]. In consequence, it is
not the death of bone cells per se that causes structural
failure, but rather, the resorption of necrotic bone and the
imbalance between formation and resorption.
Resorption is mediated by osteoclasts, recruited from their
hematopoetic origin, and occurs during or following the
revascularization of the necrotic area. Osteoclastic activity
can be reduced with bisphosphonates, a class of drugs in
clinical use for the treatment of osteoporosis, Paget's dis-
ease and osteolytic metastases. Circulating bisphospho-
nates will bind to the bone mineral. When bone is
resorbed by osteoclasts, bisphosphonates are internalized
by the cell and interfere with cell metabolism leading to
apoptosis of the osteoclast [7]. Systemic bisphosphonate
treatment can thus reduce the resorption of necrotic bone
and is well established for treatment of tumour metastases
and osteoporosis. Lately, several other applications of the
bisphosphonates have been proposed in the orthopaedic
practice, for example as treatment to reduce the risk of
structural failure and joint surface collapse after
osteonecrosis of the hip in children after SCFE and Perthes
[8] and in the adult [9-11], to prevent the collapse in
Charcot feet [12], to decrease prosthetic migration [13]
and periprosthetic osteolysis in hip replacements [14]and
to increase the strength of the regenerate in bone length-
ening [15] or bone grafting procedures [16].
Zoledronate is a new and more potent biphosphonate,
which can, just as previously shown with alendronate
[17]decrease the bone resorption during graft remodelling
but has the advantage of being more potent. Compared to
other bisphosphonates it can therefore be administered
less frequently, and in treatment of osteoporosis as sel-
dom as once a year [18]. In the present study we investi-
gate if zoledronate can be used to reduce bone graft
remodelling and if the time span between the doses can
be prolonged.
Methods
We used a model with a cancellous graft in a bone conduc-
tion chamber (BCC, Fig 1; [19]). The chamber is basically a
threaded titanium cylinder, made of two half cylinders
held together by a hexagonal screw cap. The interior of the
chamber is 7 mm long and has a diameter of 2 mm. One
end of the implant is screwed into the proximal tibia of a
rat. At this end there are two ingrowth openings where tis-
sue can grow in from the subcortical bone into a graft
placed in the chamber.
Grafts
Ten donor rats (female ca 200 g) were killed by an over-
dose of pentobarbital and bone grafts harvested from the
proximal tibias. The epiphyses and the growth plates were
discarded to remove the cartilage. A cylindrical cancellous
bone rod was taken out from each tibia in the axial direc-
tion, using a hand-held hole cutter, and frozen at -70C for
a week. At surgery, the grafts were thawed and placed in
the chambers, which then were inserted into the right leg
of the recipient animals.
Surgical procedure
Twenty male Sprague-Dawley rats (382 – 425 grams, Møl-
legaard, Copenhagen, Denmark) served as graft recipi-
ents. They were kept in animal facilities for 1 week before
experiments started (22°C; two rats in each cage, free
access to food pellets and water). The rats were anesthe-
tized with peritoneal injections of 0.6 to 0.7 mL of a solu-
tion containing pentobarbital (15 mg/mL) and diazepam
(2.5 mg/mL)
Under aseptic conditions, longitudinal incisions were
made bilaterally over the antero medial aspect of the prox-
imal tibial metaphyses. After incising and raising the peri-
osteum, the medial and posterior lateral cortices were
pierced with a 1 mm spike just anterior to the insertion of
the medial collateral ligament. The hole created in the
medial cortex was enlarged manually with a 2.7 mm drill.
The chambers were then screwed into position so that the
bone ingrowth openings were placed at the level of the
cortical bone, and the pointed end of the implant pene-
trated the opposite cortical bone. The wound was closed
leaving the entire chamber subcutaneous, palpable
through the skin but with its ingrowth openings situated
subcortically. Local anaesthetics and postoperative
buprenorfin was given for pain relief.
Injections
Postoperatively, 0.5 ml subcutaneous injections with 1.05
μg zoledronate were given at day 4 and then weekly until
harvest. The controls were given the same amount of
saline solution at the same regime.
Evaluation
The chambers were harvested after 6 weeks. The speci-
mens were fixed in 4 % formalin, decalcified, embedded
in paraffin, cut parallel to the long axis of the chamber
with a microtome and stained with haematoxylin and
eosin. Three sections from each specimen, each at 300 μmPage 2 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2006, 7:63 http://www.biomedcentral.com/1471-2474/7/63distance from the other, and showing the entire chamber
contents, were used for histological and histomorphomet-
ric analyses. All slides were investigated in random order.
The area of the new ingrown bone was measured by cir-
cumscribing it on a digitizing table using the Videoplan™
equipment (Kontron Bildanalyse GmBH, Esching, Ger-
many) at 20× screen magnification. This area includes
marrow cavities and graft remnants that had been sur-
rounded by new bone. The mean bone ingrowth distance
in each slide was calculated by dividing the new bone area
with the distance between the walls of the chamber.
The bone density in the remodelled area was evaluated
using point counting and a Merz grid at 40x screen mag-
nification. Using an ocular with 36 crossing lines, the fre-
quency of the crossings covering bone tissue was
recorded. In each 6 randomly chosen areas were analysed.
The frequencies then were then expressed as a percentage
of the total bone area. In each graft six randomly chosen
areas were measured in the mid part and the ends. The dis-
tinction between living and dead bone was based on
matrix staining, presence of osteocytes and trabecular
shape. For all measurements the data were averaged to
form a single value for each animal. The results were
tested for significance using Student's T-test. The study
was approved by the local ethical committee (M 44-03).
Results
No infection occurred. One rat died directly postopera-
tively of unknown cause. In all specimens vascularised
soft tissue (Fig 2 and 3) had invaded the whole grafts
forming a fibrotic marrow at the upper part of the speci-
men. This area was revitalized and revascularised but
without any signs of bone remodelling. The total distance
of the soft tissue ingrowth, which corresponds to the
revascularised parts of the graft, did not differ between
treated and controls (4.24 mm, SD 0.90 and 3.90 mm, SD
1.01 mm, p = 0.45).
Further down in the specimens, roughly halfway through
the graft, a zone with active new bone formation was seen
closely preceded by resorption of the graft. This new bone
ingrowth frontier marks the border of bone remodelling
where a primary bone formation occurs. A tendency
towards an increased ingrowth distance was found in the
zoledronate treated grafts (2.65 mm, SD 0.48 and 2.12
mm, SD 0.63, p = 0.052).
In the controls, this frontier of active bone formation was
thin and both the graft and the new formed bone under-
neath this primarily formed bone appeared to be immedi-
ately resorbed and replaced by a haematogenous or fatty
bone marrow (Fig 2). In contrast, in the grafts in rats
treated with zoledronate, the graft and new-formed bone
underneath the active bone formation front remained
intact with new bone lining the graft trabeculae, leaving
only little space for the marrow (Fig 3). Measuring the
bone density in the remodelled bone, i.e. both the new
bone-forming frontier as well as the more or less remod-
elled area underneath this front, the total bone volume
fraction within the remodelled area was 35% (sd13) in the
zoledronate treated grafts compared to 19% (sd 12) in the
controls (p = 0.01). Dividing the total amount of bone
into new formed and remaining graft bone, the total
amount of retained graft bone was 13% (sd 6) for the
zoledronate treated specimens compared to 5% (sd 5) in
the controls. Also the amount of new bone was increased
The bone conduction chamber in situ in the proximal tibia (T)Figure 1
The bone conduction chamber in situ in the proximal tibia 
(T). The graft (G) is placed in the chamber and mesenchymal 
tissue grows in from the bottom upwards into the bone 
graft, which subsequently remodels. Arrows point at 
ingrowth openings. (Reproduced with permission from Eur J 
Exp Musculoskel Res 2: 70, 1993).Page 3 of 7
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proportion of new-formed bone within the remodelled
area was 22% (sd 7) in the zoledronate treated grafts and
14 % (sd 9) in the controls (p = 0.03).
Discussion
Previously, we have shown alendronate to be effective in
preventing or delaying the resorption of a bone graft
[17]In the present study we show that zoledronate, a more
potent bisphosphonate is equally effective in weekly
injections as the three times a week alendronate treat-
ment. The bone chamber model is a stress-shielded model
where the resorptive stimulus is high. Normally, all graft
and new formed bone is resorbed as the remodelling is
finished and an anticatabolic drug such as a bisphospho-
nate is probably more effective than in a mechanically
loaded environment. In our experiments, we use subcuta-
neous injections, which could mean that less bisphospho-
nate is entering the systemic circulation. With higher
doses or intravenous administration, this could hypothet-
ically constitute a negative influence on bone formation.
Further, a prolonged effect of the drug with slow-release
effects could be the effect of a subcutaneous deposition
compared to an intravenous administration.
Allografts were used as a model for necrotic, autologous
bone. The strain of Sprague-Dawley rats used for this
study is, however, inbred to such an extent that no differ-
ences can be detected in the incorporation of auto- versus
allografts in this model [20]. Theoretically, it could be
A Untreated control graft after 6 weeks in the chamber Ingrowth from openings in the bottom of the chamber and upwardsFigure 2
A Untreated control graft after 6 weeks in the chamber Ingrowth from openings in the bottom of the chamber and upwards. 
At the top a vascularized fibrotic tissue has advanced furthest into the graft. The fibrotic tissue(F) is revascularized but the graft 
trabeculas (G), have not remodelled or started to resorb. The frontier of new-formed bone (NB) advances as a thin rim into 
the graft, preceeded by osteoclasts (OC). Since the graft is remodelling within a stress-shielded titanium chamber, without any 
deformation of the tissue, the new-formed bone resorb immediately. Below the new bone, therefore a marrow cavity (M) is 
formed where both the new-formed as well as the old graft bone is resorbed. (Hematoxylin Eosin × 20). B. Magnification of 
the borderzone between remodelled and resorbed bon, the front of new formed bone (Hematoxylin Eosin × 100)Page 4 of 7
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are more immunogenic than autologous bone and if so,
allografts would stimulate bone resorption even more
than an autograft. Since we wanted to study whether it is
possible to reduce bone resorption during revasculariza-
tion, such an increased tendency to resorption would
necessitate an even greater protective effect of zoledronate
in this model.
Table 1: Bone volume in the remodelled area and ingrowth distance of new bone into the graft. Bone volume fraction in the 
remodelled bone measured with Merz grid and expressed in percent of total tissue volume. Bone and vasculature ingrowth distance 
from living tissue into the graft.
Zoledronat Control p
Mean SD Mean SD
New-formed bone (%) 22 7 14 9 0.03
Remaining graft bone (%) 13 6 5 5 0.008
Total Bone (%) 35 0.12 19 0.13 0.01
Bone ingrowth distance into graft (mm) 2,65 0.48 2,12 0.63 0.052 ns
Vasculature ingrowth distance (mm) 4.2 0.90 3.90 1.01 Ns
A Zoledronate treated graft after 6 weeksFigur  3
A Zoledronate treated graft after 6 weeks. No marrow cavity has formed behind the ossification front but the graft trabeculas 
below are still remaining to a large extent. The total amount of bone, both newly formed and remaining graft bone is higher in 
the remodelled area compared to the control. (Hematoxylin Eosin × 20). B Magnification of the borderzone with retained 
trabeculas in the remodelled area.Page 5 of 7
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for orthopaedic applications of bisphosphonates, relating
to the ability of the substance to decrease the resorption of
necrotic bone during revascularization and remodelling
after an avascular necrosis. It appears that bone under
remodelling can retain its form better if the remodelling is
slowed down by for example a bisphosphonate [4-6].
Still, there are concerns that bisphosphonates might inter-
fere with the normal fracture and bone healing [21]. The-
oretically, the bone stock can be negatively influenced,
both in the long run, by decreasing the ability to maintain
and repair microfractures over years, but also in the short
term by interfering with the bone formation. Osteoclasts
are necessary for bone formation by the osteoblasts.
Regarding the concern for long time complications, long
time follow-up data regarding alendronate does not show
an increased fracture rate in patients on osteoporosis
prophylaxis treatment for up to 10 year [22]. Zoledronate,
however, is more potent than alendronate and could
hypothetically interfere more, but no corresponding long
time data exist. Regarding the fear to use a bisphospho-
nate for the short term influence on fracture healing, the
results of the present and other recent experiments, using
bone chambers as a model for remodelling of a graft or
necrotic bone show, not only a decreased resorption as
expected, but also an increased amount of new bone in
the remodelled area. Although non-significant, a ten-
dency towards an increased bone ingrowth distance or
speed was noticed. One could interpret these results as if
bisphosphonates would be not be merely an anticata-
bolic, but also function as an anabolic substance as
hypothesized in some in vitro [23,24] and in vivo studies
[25]. Bisphosphonates are for example found to have an
antiapoptotic effect in osteocytes and osteoblasts [26], but
several other explanations to the findings of an increased
amount of newly formed bone can, however, be dis-
cussed. In contrast to cortical bone, remodelling in cancel-
lous bone does not require cutting cones to make space
for new bone. In cancellous bone there is sufficient space
for new bone to form and often the new bone formation
appears as appositional growth, covering the dead bone
graft, which is not resorbed because it is bisphosphonate
treated. In consequence, a larger surface area exists to lay
down new forming bone onto (Fig 3). The fact that we
find an increased amount of newly formed bone does not
necessarily mean that more bone has formed or that
zoledronate by any means is anabolic. New-formed bone
might simply just prevail for a longer period if bone
resorption is reduced. With the bisphosphonates, most of
the calcified tissue that was present or has formed since
the remodelling of the graft started will remain, both the
old graft bone as well as the newly formed bone growing
into the graft.
Regardless of reason, bone formation during bone graft
remodelling was not decreased when treated with
bisphosphonate in our study. On the contrary, more bone
was found within the remodelled graft, both old graft and
newly formed. Bisphosphonate treatment might, how-
ever, erroneously mimic an increased new bone forma-
tion, due to the absent resorption of the new formed
bone.
Conclusion
We show that zoledronate can be used to decrease the
resorption of both old graft and new-formed bone during
bone graft remodelling. This might be useful in bone
grafting procedure but also in other orthopedic condi-
tions, both where necrotic bone has to be remodelled i.e.
after osteonecrosis of the knee and hip and in Perthes dis-
ease, or in high load, high turnover conditions like
delayed union, periprosthetic osteolysis or bone length-
ening operations. In our model an increased net forma-
tion of new bone was found which probably reflects that
new formed was retained by the action of the bisphospho-
nates rather than a true anabolic effect.
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